Which has better earnings and valuation, ANL or VKTX?

Adlai Nortye has higher revenue and earnings than Viking Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 183.15 -$35.53M N/A N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is ANL or VKTX more profitable?

Adlai Nortye's return on equity of 0.00% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Viking Therapeutics N/A -94.56% -82.75%

Does the media favor ANL or VKTX?

In the previous week, Viking Therapeutics had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 10 mentions for Viking Therapeutics and 8 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat Viking Therapeutics' score of 0.43 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ANL or PBLS?

Adlai Nortye has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 183.15 -$35.53M N/A N/A Parabilis Medicines N/A N/A -$145.89M -$2.13 N/A

Is ANL or PBLS more profitable?

Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Parabilis Medicines N/A N/A N/A

Does the media favor ANL or PBLS?

In the previous week, Adlai Nortye had 5 more articles in the media than Parabilis Medicines. MarketBeat recorded 8 mentions for Adlai Nortye and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Adlai Nortye's score of 0.80 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ANL or XENE?

Adlai Nortye has higher earnings, but lower revenue than Xenon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 183.15 -$35.53M N/A N/A Xenon Pharmaceuticals $7.50M 461.57 -$345.91M -$4.74 N/A

Is ANL or XENE more profitable?

Adlai Nortye's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media prefer ANL or XENE?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 10 mentions for Xenon Pharmaceuticals and 8 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat Xenon Pharmaceuticals' score of 0.59 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher earnings & valuation, VCYT or ANL?

Veracyte has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 6.84 $66.35M $1.41 31.22 Adlai Nortye $5M 183.15 -$35.53M N/A N/A

Does the media refer more to VCYT or ANL?

In the previous week, Veracyte and Veracyte both had 8 articles in the media. Adlai Nortye's average media sentiment score of 0.80 beat Veracyte's score of 0.54 indicating that Adlai Nortye is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ANL or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 183.15 -$35.53M N/A N/A ACADIA Pharmaceuticals $1.07B 3.12 $391M $2.22 8.74

Does the media prefer ANL or ACAD?

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 8 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat ACADIA Pharmaceuticals' score of 0.16 indicating that Adlai Nortye is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adlai Nortye 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Adlai Nortye (ANL) Competitors

$11.76 -2.46 (-17.30%)

Closing price 04:00 PM Eastern

Extended Trading

$11.84 +0.08 (+0.68%)

As of 06:32 PM Eastern

Compare

ANL vs. VKTX, PBLS, XENE, VCYT, and ACAD

Should you buy Adlai Nortye stock or one of its competitors? Adlai Nortye's main competitors and comparable companies include Viking Therapeutics (VKTX), Parabilis Medicines (PBLS), Xenon Pharmaceuticals (XENE), Veracyte (VCYT), and ACADIA Pharmaceuticals (ACAD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adlai Nortye compare to Viking Therapeutics?

Adlai Nortye (NASDAQ:ANL) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adlai Nortye has higher revenue and earnings than Viking Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	183.15	-$35.53M	N/A	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Adlai Nortye's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Viking Therapeutics	N/A	-94.56%	-82.75%

Adlai Nortye has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Adlai Nortye presently has a consensus price target of $29.50, suggesting a potential upside of 107.45%. Viking Therapeutics has a consensus price target of $99.44, suggesting a potential upside of 250.90%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Viking Therapeutics had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 10 mentions for Viking Therapeutics and 8 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat Viking Therapeutics' score of 0.43 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adlai Nortye beats Viking Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Adlai Nortye compare to Parabilis Medicines?

Adlai Nortye (NASDAQ:ANL) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Parabilis Medicines	N/A	N/A	N/A

In the previous week, Adlai Nortye had 5 more articles in the media than Parabilis Medicines. MarketBeat recorded 8 mentions for Adlai Nortye and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Adlai Nortye's score of 0.80 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	183.15	-$35.53M	N/A	N/A
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A

35.2% of Adlai Nortye shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adlai Nortye currently has a consensus price target of $29.50, indicating a potential upside of 107.45%. Parabilis Medicines has a consensus price target of $41.67, indicating a potential upside of 43.93%. Given Adlai Nortye's stronger consensus rating and higher possible upside, research analysts plainly believe Adlai Nortye is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Adlai Nortye beats Parabilis Medicines on 7 of the 8 factors compared between the two stocks.

How does Adlai Nortye compare to Xenon Pharmaceuticals?

Adlai Nortye (NASDAQ:ANL) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Adlai Nortye's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Adlai Nortye has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Adlai Nortye currently has a consensus price target of $29.50, suggesting a potential upside of 107.45%. Xenon Pharmaceuticals has a consensus price target of $70.14, suggesting a potential upside of 95.88%. Given Adlai Nortye's higher possible upside, research analysts plainly believe Adlai Nortye is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Adlai Nortye has higher earnings, but lower revenue than Xenon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	183.15	-$35.53M	N/A	N/A
Xenon Pharmaceuticals	$7.50M	461.57	-$345.91M	-$4.74	N/A

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 10 mentions for Xenon Pharmaceuticals and 8 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat Xenon Pharmaceuticals' score of 0.59 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

How does Adlai Nortye compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Adlai Nortye (NASDAQ:ANL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Veracyte has a net margin of 20.37% compared to Adlai Nortye's net margin of 0.00%. Veracyte's return on equity of 9.26% beat Adlai Nortye's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Adlai Nortye	N/A	N/A	N/A

35.2% of Adlai Nortye shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Veracyte has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Veracyte presently has a consensus target price of $55.78, indicating a potential upside of 26.71%. Adlai Nortye has a consensus target price of $29.50, indicating a potential upside of 107.45%. Given Adlai Nortye's stronger consensus rating and higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Veracyte has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.84	$66.35M	$1.41	31.22
Adlai Nortye	$5M	183.15	-$35.53M	N/A	N/A

In the previous week, Veracyte and Veracyte both had 8 articles in the media. Adlai Nortye's average media sentiment score of 0.80 beat Veracyte's score of 0.54 indicating that Adlai Nortye is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veracyte beats Adlai Nortye on 8 of the 13 factors compared between the two stocks.

How does Adlai Nortye compare to ACADIA Pharmaceuticals?

Adlai Nortye (NASDAQ:ANL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

ACADIA Pharmaceuticals has higher revenue and earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	183.15	-$35.53M	N/A	N/A
ACADIA Pharmaceuticals	$1.07B	3.12	$391M	$2.22	8.74

Adlai Nortye currently has a consensus target price of $29.50, suggesting a potential upside of 107.45%. ACADIA Pharmaceuticals has a consensus target price of $32.71, suggesting a potential upside of 68.52%. Given Adlai Nortye's stronger consensus rating and higher probable upside, research analysts clearly believe Adlai Nortye is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, ACADIA Pharmaceuticals had 5 more articles in the media than Adlai Nortye. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 8 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.80 beat ACADIA Pharmaceuticals' score of 0.16 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adlai Nortye	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Adlai Nortye has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Adlai Nortye's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Adlai Nortye's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Summary

ACADIA Pharmaceuticals beats Adlai Nortye on 9 of the 15 factors compared between the two stocks.

Get Adlai Nortye News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANL vs. The Competition

Export

Metric	Adlai Nortye	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$757.34M	$3.82B	$7.16B	$13.16B
Dividend Yield	N/A	3.65%	2.52%	20.73%
P/E Ratio	N/A	12.90	275.97	25.79
Price / Sales	151.47	1,176.95	617.33	101.37
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	-56.00	16.95	10.68	6.03
Net Income	-$35.53M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-18.67%	-4.83%	-3.17%	-3.04%
1 Month Performance	-22.68%	-12.20%	-6.61%	-5.16%
1 Year Performance	619.27%	8.87%	3.69%	-2.48%

Adlai Nortye Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANL Adlai Nortye	2.2257 of 5 stars	$11.76 -17.3%	$29.50 +150.9%	+761.8%	$757.34M	$5M	N/A	109	Analyst Forecast High Trading Volume
VKTX Viking Therapeutics	3.3224 of 5 stars	$28.54 +0.6%	$99.44 +248.4%	-15.6%	$3.60B	N/A	N/A	65
PBLS Parabilis Medicines	2.1971 of 5 stars	$28.82 -0.1%	$41.67 +44.6%	N/A	$3.56B	N/A	N/A	145
XENE Xenon Pharmaceuticals	4.4154 of 5 stars	$36.41 -0.4%	$70.14 +92.6%	-9.7%	$3.52B	$7.50M	N/A	364	Analyst Downgrade
VCYT Veracyte	4.2723 of 5 stars	$43.16 -3.3%	$55.78 +29.2%	+26.5%	$3.47B	$517.15M	30.61	755	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANL) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adlai Nortye (ANL) Competitors

ANL vs. VKTX, PBLS, XENE, VCYT, and ACAD

How does Adlai Nortye compare to Viking Therapeutics?

Summary

How does Adlai Nortye compare to Parabilis Medicines?

Summary

How does Adlai Nortye compare to Xenon Pharmaceuticals?

Summary

How does Adlai Nortye compare to Veracyte?

Summary

How does Adlai Nortye compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adlai Nortye (ANL) Competitors

ANL vs. VKTX, PBLS, XENE, VCYT, and ACAD

How does Adlai Nortye compare to Viking Therapeutics?

Do institutionals & insiders have more ownership in ANL or VKTX?

Which has better earnings and valuation, ANL or VKTX?

Is ANL or VKTX more profitable?

Which has more risk and volatility, ANL or VKTX?

Do analysts prefer ANL or VKTX?

Does the media favor ANL or VKTX?

Summary

How does Adlai Nortye compare to Parabilis Medicines?

Is ANL or PBLS more profitable?

Does the media favor ANL or PBLS?

Which has better earnings and valuation, ANL or PBLS?

Do insiders & institutionals hold more shares of ANL or PBLS?

Do analysts rate ANL or PBLS?

Summary

How does Adlai Nortye compare to Xenon Pharmaceuticals?

Is ANL or XENE more profitable?

Do institutionals and insiders hold more shares of ANL or XENE?

Which has more risk & volatility, ANL or XENE?

Do analysts prefer ANL or XENE?

Which has better valuation & earnings, ANL or XENE?

Does the media prefer ANL or XENE?

Summary

How does Adlai Nortye compare to Veracyte?

Is VCYT or ANL more profitable?

Do institutionals & insiders believe in VCYT or ANL?

Which has more risk and volatility, VCYT or ANL?

Do analysts rate VCYT or ANL?

Which has higher earnings & valuation, VCYT or ANL?

Does the media refer more to VCYT or ANL?

Summary

How does Adlai Nortye compare to ACADIA Pharmaceuticals?

Which has stronger earnings and valuation, ANL or ACAD?

Do analysts prefer ANL or ACAD?

Does the media prefer ANL or ACAD?

Which has more risk and volatility, ANL or ACAD?

Do insiders and institutionals hold more shares of ANL or ACAD?

Is ANL or ACAD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANL vs. The Competition

Adlai Nortye Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools